期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 55, 期 13, 页码 1283-1299出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2010.01.008
关键词
high-density lipoprotein; coronary artery disease; prognosis; prevention
资金
- Bristol-Myers Squibb
- Pfizer
- Accumetrics
- AstraZeneca
- Bristol-Myers Squibb/Sanofi Partnership
- GlaxoSmithKline
- Intekrin Therapeutics
- Merck
- Merck/Schering-Plough Partnership
- Novartis
- Takeda
Coronary heart disease remains a major cause of worldwide morbidity and mortality despite therapeutic advances that control many risk factors such as low-density lipoprotein cholesterol to levels lower than previously possible. Population studies have consistently demonstrated an inverse association between high-density lipoprotein cholesterol (HDL-C) levels with the risk of coronary heart disease. As a result, HDL-C is gaining increasing interest as a therapeutic target. In this review, we explore the protective mechanisms of HDL and how current and future therapies harness these beneficial properties. We offer a biological framework to understand treatment strategies as well as their resultant successes and failures to guide management and future directions. At present, raising HDL-C level holds great promise, on the basis of epidemiology and initial trials, but we await the outcomes of the many large clinical outcomes trials currently under way to define the clinical role of older and novel therapies to raise HDL-C level. (J Am Coll Cardiol 2010; 55: 1283-99) (C) 2010 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据